Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

QR Code

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

Nasser G Alsaedi,1,2 Ruba M Alselaimy,3 Abdulaziz A Alshamrani,1 Muhammed AlAjmi,4 Rajiv Khandekar,1 Hassan Al-Dhibi,1 Abdulelah A Al-Abdullah1 1King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; 2King Abdullah Medical City, Makkah, Saudi Arabia; 3College of Medicine, King Saud University, R...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Alsaedi NG, Alselaimy RM, Alshamrani AA, AlAjmi M, Khandekar R, Al-Dhibi H, Al-Abdullah AA
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2021
Sujets:	aflibercept bevacizumab persistent dme ranibizumab vegf switch vascular endothelial growth factor Ophthalmology RE1-994
Accès en ligne:	https://doaj.org/article/6c17e55774c24a50b1c2e43f1d1e0882
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
par: Pessoa B, et autres
Publié: (2021)

Managing Diabetic Macular Edema in Clinical Practice: Systematic Review and Meta-Analysis of Current Strategies and Treatment Options
par: Veritti D, et autres
Publié: (2021)

Results of switchback from ranibizumab to aflibercept in patients with exudative age-related macular degeneration
par: Koike N, et autres
Publié: (2019)

Evaluation of contrast sensitivity and other visual function outcomes in diabetic macular edema patients following treatment switch to aflibercept from ranibizumab
par: Nixon DR, et autres
Publié: (2018)

Intravitreal aflibercept versus intravitreal ranibizumab for the treatment of diabetic macular edema
par: Fouda SM, et autres
Publié: (2017)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
par: Xiu-Xian Wang, et autres
Publié: (2021)

Ranibizumab treatment history as predictor of the switch-response to aflibercept: evidence for drug tolerance
par: Dirani A, et autres
Publié: (2018)

Short-term outcomes in patients with branch retinal vein occlusion who received intravitreal aflibercept with or without intravitreal ranibizumab
par: Sakanishi Y, et autres
Publié: (2017)

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis
par: Kiss S, et autres
Publié: (2018)

Anatomical and functional response after conversion to aflibercept using the treat-and-extend regimen protocol in bevacizumab treatment-resistant wet age-related macular degeneration
par: Taipale C, et autres
Publié: (2018)

Relationship between aqueous humor cytokine level changes and retinal vascular changes after intravitreal aflibercept for diabetic macular edema
par: Rodolfo Mastropasqua, et autres
Publié: (2018)

Contralateral eye-to-eye comparison of intravitreal ranibizumab and a sustained-release dexamethasone intravitreal implant in recalcitrant diabetic macular edema
par: Thomas BJ, et autres
Publié: (2016)

Prolongation of injection interval after switching therapy from ranibizumab to aflibercept in Japanese patients with macular edema secondary to branch retinal vein occlusion
par: Tagami M, et autres
Publié: (2017)

Immediate sequential bilateral intravitreal injections: an Indian perspective
par: Tripathy K
Publié: (2017)

Two-year outcome of treat-and-extend aflibercept after ranibizumab in age-related macular degeneration and polypoidal choroidal vasculopathy patients
par: Azuma K, et autres
Publié: (2018)

Axial length, refraction, and retinal vascularization 1 year after ranibizumab or bevacizumab treatment for retinopathy of prematurity
par: Lin CJ, et autres
Publié: (2016)

Timing of neovascular regression in eyes with high-risk proliferative diabetic retinopathy without macular edema treated initially with intravitreous bevacizumab
par: Shakarchi FI, et autres
Publié: (2018)

Grid laser with modified pro re nata injection of bevacizumab and ranibizumab in macular edema due to branch retinal vein occlusion: MARVEL report no 2
par: Narayanan R, et autres
Publié: (2016)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
par: Tran THC, et autres
Publié: (2021)

Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in clinical practice (ECHO study report 2)
par: Jumper JM, et autres
Publié: (2018)

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
par: Spooner K, et autres
Publié: (2017)

Evaluation of the Safety of Bilateral Same-Day Intravitreal Injections of Anti-Vascular Endothelial Growth Factor Agents: Experience of a Large Korean Retina Center
par: Jang K, et autres
Publié: (2020)

Evaluation of contrast sensitivity and other visual function outcomes in neovascular age-related macular degeneration patients after treatment switch to aflibercept from ranibizumab
par: Nixon DR, et autres
Publié: (2017)

One-year outcome of intravitreal aflibercept injection for age-related macular degeneration resistant to ranibizumab: rapid morphologic recovery and subsequent visual improvement
par: Hirakata T, et autres
Publié: (2016)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
par: Nudleman E, et autres
Publié: (2016)

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better
par: Khanani AM, et autres
Publié: (2019)

Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
par: Jia-Kang Wang, et autres
Publié: (2018)

Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model
par: Zhuang Cui, et autres
Publié: (2021)

Intravitreal aflibercept for choroidal neovascularization associated with chorioretinitis: a pilot study
par: Korol AR, et autres
Publié: (2017)

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
par: Laine I, et autres
Publié: (2017)

Update on corticosteroids for diabetic macular edema
par: Schwartz SG, et autres
Publié: (2016)

Association of treatment adherence with real-life VA outcomes in AMD, DME, and BRVO patients
par: Ehlken C, et autres
Publié: (2017)

Anti-Angiogenic Activity Of Bevacizumab-Bearing Dexamethasone-Loaded PLGA Nanoparticles For Potential Intravitreal Applications
par: Liu J, et autres
Publié: (2019)

Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema
par: Fong AH, et autres
Publié: (2013)

Changing from bevacizumab to ranibizumab in age-related macular degeneration. Is it safe?
par: Dimitrios A Karagiannis, et autres
Publié: (2009)

Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials
par: Singer M, et autres
Publié: (2020)

Effectiveness of prophylactic intravitreal bevacizumab injection to proliferative diabetic retinopathy patients with elevated preoperative intraocular VEGF in preventing complications after vitrectomy
par: Tsubota K, et autres
Publié: (2019)

Genetic Polymorphisms Affecting Ranibizumab Response in High Myopia Patients
par: David Blánquez-Martínez, et autres
Publié: (2021)

Conversion to aflibercept for diabetic macular edema unresponsive to ranibizumab or bevacizumab
par: Lim LS, et autres
Publié: (2015)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
par: Paulose R, et autres
Publié: (2016)